Journal of Infection
Volume 61, Issue 2 , Pages 190-192 , August 2010

Natural killer cells during primary varicella zoster virus infection

  • Graham S. Ogg

      Affiliations

    • Corresponding Author InformationCorresponding author. Cutaneous Immunology Group, Weatherall Institute of Molecular Medicine, Oxford, OX3 9DS, UK. Tel.: +44(0) 1865 222334; fax: +44(0) 1865 222502.

,Accepted 25 May 2010.

References 

  1. Tunbridge AJ, Breuer J, Jeffery KJ. Chickenpox in adults – clinical management. J Infect. 2008 Aug;57(2):95–102
  2. Malavige GN, Jones L, Kamaladasa SD, Wijewickrama A, Seneviratne SL, Black AP, et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One. 2008;3(11):e3789
  3. Romagnani C, Juelke K, Falco M, Morandi B, D’Agostino A, Costa R, et al. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007 Apr 15;178(8):4947–4955
  4. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol. 2007 Jul 1;179(1):89–94
  5. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, et al. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16− CD56bright NK Cells but also from CD16− CD56dim NK cells. Scand J Immunol. 2007 Feb;65(2):126–138
  6. Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008 Apr;123(4):575–583
  7. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol. 2004 Jan 1;172(1):88–96
  8. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 2002 Dec;4(15):1545–1558
  9. Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, et al. Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci. 2007 Jan;1096:37–43
  10. Mossman KL, Ashkar AA. Herpesviruses and the innate immune response. Viral Immunol. 2005;18(2):267–281
  11. Reading PC, Whitney PG, Barr DP, Smyth MJ, Brooks AG. NK cells contribute to the early clearance of HSV-1 from the lung but cannot control replication in the central nervous system following intranasal infection. Eur J Immunol. 2006 Apr;36(4):897–905
  12. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol. 2001 May;75(10):4878–4888
  13. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001 Mar 29;344(13):955–960
  14. Quinlivan ML, Ayres K, Ran H, McElwaine S, Leedham-Green M, Scott FT, et al. Effect of viral load on the outcome of herpes zoster. J Clin Microbiol. 2007 Sep 12;
  15. Lima M, Goncalves C, Teixeira MA, Franca M, Canelhas A, Pina R, et al. Aggressive natural-killer cell lymphoma presenting with skin lesions, breast nodule, suprarenal masses and life-threatening pericardial and pleural effusions. Leuk Lymphoma. 2001 Nov–Dec;42(6):1385–1391
  16. Root LL, Shipley GD. Normal human fibroblasts produce membrane-bound and soluble isoforms of FGFR-1. Mol Cell Biol Res Commun. 2000 Feb;3(2):87–97

PII: S0163-4453(10)00152-0

doi: 10.1016/j.jinf.2010.05.004

Journal of Infection
Volume 61, Issue 2 , Pages 190-192 , August 2010

Article Tools

* Image Usage & Resolution